FDA Approves Dasatinib for Pediatric Patients With CML
Nov 08
2017
The Food and Drug Administration granted regular approval to dasatinib (SPRYCEL®, Bristol-Myers Squibb Co.) for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
